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Objectives: To assess the effect of a pharmacist telephone counseling intervention on
patients’ medication adherence.
Design: Pragmatic cluster randomized controlled trial.
Setting: 53 Community pharmacies in The Netherlands.
Participants: Patients ≥18 years initiating treatment with antidepressants,
bisphosphonates, Renin-Angiotensin System (RAS)-inhibitors, or statins (lipid lowering
drugs). Pharmacies in arm A provided the intervention for antidepressants and
bisphosphonates and usual care for RAS-inhibitors and statins. Pharmacies in
arm B provided the intervention for RAS-inhibitors and statins and usual care for
antidepressants and bisphosphonates.
Intervention: Intervention consisted of a telephone counseling intervention 7–21 days
after the start of therapy. Counseling included assessment of practical and perceptual
barriers and provision of information and motivation.
Main outcome measure: Primary outcome was refill adherence measured over 1
year expressed as continuous outcome and dichotomous (refill rate≥80%). Secondary
outcome was discontinuation within 1 year.
Results: In the control arms 3627 patients were eligible and in the intervention arms
3094 patients. Of the latter, 1054 patients (34%) received the intervention. Intention to
treat analysis showed no difference in adherence rates between the intervention and the
usual care arm (74.7%, SD 37.5 respectively 74.5%, 37.9). More patients starting with
RAS-inhibitors had a refill ratio ≥80% in the intervention arm compared to usual care
(81.4 vs. 74.9% with odds ratio (OR) 1.43, 95%CI 1.11–1.99). Comparing patients with
counseling to patients with usual care (per protocol analysis), adherence was statistically
significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates.
Patients initiating antidepressants did not benefit from the intervention.
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Conclusions: Telephone counseling at start of therapy improved adherence in patients
initiating RAS-inhibitors. The per protocol analysis indicated an improvement for lipid
lowering drugs and bisphosphonates. No effect for on adherence in patients initiating
antidepressants was found.
The trial was registered at www.trialregister.nl under the identifier NTR3237.
Keywords: medication adherence, intervention, counseling, pharmaceutical care, statins, antidepressant,
bisphosphonate, RAS-inhibitor
INTRODUCTION
Adherence to medication is a primary determinant of treatment
success, and it is often suboptimal (Sabaté, 2003). Practical
and perceptual barriers can prevent patients from adhering
to the prescribed regimen. Practical barriers predominantly
relate to cognition and self-efficacy whereas perceptual barriers
predominantly relate to beliefs about the necessity and drawbacks
of drug treatment (Linn et al., 2012). Health care providers
(HCP) including pharmacists can reduce these barriers and
thereby promote adherence (van Dulmen et al., 2007; Blom
and Krass, 2011; van Hulten et al., 2011). Pharmacists have
frequent interactions with patients, are easy accessible, well-
trained and educated. Guidelines recommend counseling by
pharmacists to improve medication adherence, especially at
the start of therapy (1997; Puspitasari et al., 2009; Blom and
Krass, 2011; van Hulten et al., 2011; Mendys et al., 2014).
The first dispensing of a new drug, should be accompanied
with general information and instructions for use. At the
first refill, counseling should focus on exploring patients’
experiences with the medication. In daily clinical practice,
however guidelines are often not followed (Puspitasari et al.,
2009; Van de Steeg-van Gompel et al., 2011; Schwappach
et al., 2012) resulting in suboptimal counseling (Zolnierek
and Dimatteo, 2009; Greenhill et al., 2011; Linn, 2013). The
reasons for deviating from guidelines by pharmacists can
be patient related (e.g., the patient is unable to visit the
pharmacy, there are language problems, or the patient has
low health literacy skills). Reasons can also be pharmacy
or health system related (e.g., the pharmacy is understaffed,
there is no priority for counseling, there is a lack of privacy
or lack of remuneration). Telephone counseling may be a
feasible alternative for face-to-face counseling (Elliott et al.,
2008; Feifer et al., 2010). It has several advantages: first of all
patient may be more comfortable when approached in their
own environment where (lack) of privacy is not an issue.
Moreover patients who are not able to visit the pharmacy
can be reached. Also, pharmacists can prepare themselves on
the call and the telephone calls can be planned (if necessary
outside office hours). To test the effect of counseling by
telephone on adherence, we designed a cluster randomized
trial. Clusters (pharmacies) were randomized to increase the
feasibility of including patients at the pharmacy counter. Primary
goal of this study was to assess the effect of a pharmacist
telephone counseling intervention on patients’ medication
adherence.
METHODS
Study Design
The protocol for this multicentre, community pharmacy based,
cluster randomized controlled trial (the TelCIP trial) has been
described elsewhere (Kooy et al., 2014). Pharmacies were
randomized in two arms in a 1:1 ratio. Patients in arm A
starting with antidepressants or bisphosphonates and patients
in arm B starting with RAS-inhibitors or statins received the
intervention. Patients in arm A starting with RAS-inhibitors or
statins and patients in arm B starting with antidepressants or
bisphosphonates received usual care (see Figure 1).
Participants
Pharmacies
The study was conducted in community pharmacies in the
Netherlands, both in rural and urban areas. No specific eligibility
criteria for clusters were defined. Within every pharmacy
one dedicated staff member was assigned to perform the
intervention. This could be the pharmacist (PharmD) or a non-
pharmacist employee with a bachelor degree (B), pharmacist
trainee (BPharm) or pharmacy technician. In this paper we
used the term pharmacist to describe all these staff members
unless stated otherwise. The term pharmacy practitioner was
used for bachelors and trainees. Pharmacists received a 3 h
training aimed at understanding beliefs and behavior of patients
related to medication intake. The training included case studies
and an assessment of the level of theoretical knowledge on
communication (Kooy et al., 2014). Pharmacist trainees did not
receive additional training since communication is a currently
taught throughout the curriculum (Blom et al., 2011, 2014).
Patients
Inclusion criteria were:
• Aged ≥ 18 years
• Speaking Dutch or same language as pharmacist/pharmacy
worker
• Receiving a prescription for one of the fore mentioned
medication classes for the first time in 12 months (Kooy et al.,
2014).
Patients were excluded if the medication was prescribed for a
short-term indication (e.g., antidepressant for smoking cessation
or sleeping disorders), had a severe mental illness or were not
responsible for their own drug intake. Patients were recruited
between October 2010 and March 2013.
Frontiers in Pharmacology | www.frontiersin.org 2 August 2016 | Volume 7 | Article 269
Kooij et al. Telephone Counseling and Medication Adherence
FIGURE 1 | Practice and patients flowchart. This figure outlines the progress of clusters (pharmacies) and individual patients through the phases of the trial.
Numbers are patients unless stated otherwise.
Procedure
Usual Care
Professional guidelines emphasize that patients receive both
written and oral information at the start of pharmacotherapy.
In practice this is mostly done by a pharmacy technician.
The first dispensing provides medication for a maximum of 2
weeks. Guidelines recommend that at the first refill, patients are
asked about their experiences with the medication. If necessary,
additional information or counseling should be provided.
Intervention Arm
Patients in the intervention arms were selected weekly through
an automated selection procedure. Subsequently the pharmacist
contacted patients by telephone between 7 and 21 days after
the first prescription. Main goal of this call was to improve
adherence. The call was supported by a pre-tested interview
protocol aimed at addressing the following subjects: (1) need for
information; (2) actual medication intake behavior; (3) practical
barriers including side effects; (4) perceptual barriers including
concerns or low necessity beliefs. The protocol was medication
class specific and items like specific side effects and intake advices
were included. A general interview protocol has been published
elsewhere, together with the study protocol (Kooy et al., 2014).
Data Collection
Pharmacy dispensing data were collected covering all
prescriptions from at least 12 months before and after the
intervention. These data included dispensing date, quantity
dispensed, prescribed daily dose and prescriber.
Outcome Measures
The primary outcome was patients’ refill adherence [Medication
Possession Ratio modified, MPRm (Hess et al., 2006)] in the
year following start of medication therapy, and was expressed
both as a continuous and as a dichotomous measure; patients
with an MPRm≥80% were considered adherent. The MPRm was
calculated by dividing the total number of days’ supply of a drug,
excluding the last supply, by the number of days between the first
and the last dispensing or first discontinuation date within the
year after the start, whichever came first. The number of days
supplied was calculated by dividing quantity dispensed by the
prescribed daily dose. In case of missing dosing instructions, the
instruction of the previous dispensing or the next dispensing (in
case of a first prescription) was used. Retrospective compensation
was not allowed.
Secondary outcome was persistence, which was expressed as
the time from initiation until discontinuation. Discontinuation
was defined as exceeding a gap of 90 days with no medication
available within the 1-year observation period.
Treatment Fidelity
Treatment fidelity was promoted through the design of the study,
by providing training to pharmacists, by providing a manual, an
interview protocol and an online self-report (Borrelli, 2011). The
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self-report contained all items from the interview protocol and
was used for continuously monitoring of implementation and
for assessment of treatment fidelity. The pharmacists registered
information on duration of the calls and number of attempts
as well as the topics discussed and additional interventions
performed. Reasons for not including a selected patient were also
registered.
Sample Size
Sample size calculation was based on the primary outcome, the
proportion of adherent patients (MPRm≥80%), using a type one
error (α) for a two sided test of 0.05 and a power of 0.80 (1-β).
To demonstrate an improvement of the proportion of adherent
patients from 70 to 80%, an individually randomized trial would
need 294 patients per arm and per medication class (Campbell
et al., 1995). Correcting for clustering effects using an intracluster
(or intraclass) correlation coefficient (ICC) of 0.02 resulted in the
inclusion of at least 15 pharmacies with at least 30 patients each
(Campbell et al., 1995; Eccles et al., 2003; Evans et al., 2009, 2010;
Kooy et al., 2014).
Data Analysis
The primary analysis was based on the intention to treat (ITT)
principle and the four medication classes were pre-defined
subgroups. In a secondary, per protocol (PP) analysis, we
compared patients in the intervention arm who actually received
counseling, to patients in the usual care arm. Effect analyses
were performed by a statistician (SB) blinded to the group
allocation. Linear mixed-effects models were used for continuous
outcomes and generalized mixed-effect models with the logit
link function were used for dichotomous outcomes, both with
pharmacy as random effect and percentile bootstrap confidence
intervals with 1000 replications. Discontinuation in the first year
was assessed using the Cox proportional hazards frailty model
with the pharmacy as a random frailty factor. We considered
a p < 0.05 to be statistically significant. For the descriptive
and effect analyses we used R software version 3.1.2. (Austria,
www.R-project.org). For multilevel analysis, library “lme4” was
used with “lmer” function for continuous outcomes, “glmer”
function for dichotomous outcomes and “survival” function
for Cox regression. In a secondary, exploratory analysis we
tested several factors as potential modifying factors: age, gender,
Chronic Disease Score (CDS), and the status score at baseline.
The CDS uses medication dispensed, as a surrogate marker for
chronic illness (Von Korff et al., 1992). The status score (SS) is
used as a marker for the individual socioeconomic status (SES).
The SS is based on the patient’s postal code and uses the average
income, income, education and employment of persons living in
that area (The statusscore presented by The Netherlands Institute
for Social Research, 2014).
Ethics and Confidentiality
TheMedical Ethics Review Committee (METC) of the University
Medical Centre Utrecht has considered our research proposal
in a meeting on 13 July 2010 and concluded that the Dutch
Medical Research Involving Human Subjects Act (WMO) was
not applicable. Consequently the protocol was submitted to the
departmental Institutional Review Board (IRB) which approved
the study protocol. The trial was registered at www.trialregister.nl
under the identifier NTR3237. Patients received an information
letter and gave informed consent before participating. All patient
data were anonymised at the pharmacies.
RESULTS
Of 62 pharmacies that included patients in the study, dispensing
data were available from 53 pharmacies (25 arm A and 28 arm B)
(see Figure 1). In total 6731 patients were eligible (3627 control
patients and 3094 intervention patients). A telephone call was
registered for 1054 (34%) of the 3094 patients in the intervention
arm. For 545 (18%) patients it was registered that the patient
did not receive the intervention and for 1495 (48%) patients no
registration was found.
Overall, patients in the intervention arm were younger and
more often female (Table 1). However this was mainly due to
TABLE 1 | Baseline socio-demographic and health characteristics for
each group at individual level.
Characteristic Usual Eligible Patients with
care patients (ITT) counseling (PP)
Overall n = 3637 n = 3094 n = 1054
Mean (SD) age, years 59.0 (15.1) 56.9 (15.9) 58.6 (15.8)
Female, n (%) 1987 (54.6) 1785 (57.7) 644 (61.1)
Mean (SD) status score −0.44 (1.29) −0.31 (1.20) −0.43 (1.27)
Mean (SD) CDS 3.3 (3.1) 3.1 (3.1) 3.4 (3.2)
Patients starting with
RAS-inhibitor
n = 1317 n = 850 n = 257
Mean (SD) age, years 61.1 (13.7) 62.2 (13.0) 63.8 (12.2)
Female, n (%) 710 (53.9) 439 (51.6) 145 (56.4)
Mean (SD) status score −0.62 (1.32) −0.01 (1.06) −0.08 (1.18)
Mean (SD) CDS 3.3 (3.1) 3.3 (3.0) 3.5 (2.9)
Patients starting with
statin
n = 1345 n = 839 n = 268
Mean (SD) age, years 60.6 (12.6) 61.6 (11.5) 62.5 (11.3)
Female, n (%) 660 (49.1) 414 (49.3) 139 (51.9)
Mean (SD) status score −0.60 (1.29) −0.02 (0.97) −0.01 (0.98)
Mean (SD) CDS 3.4 (2.9) 3.4 (2.8) 3.6 (2.8)
Patients starting with
bisphosphonate
n = 252 n = 319 n = 137
Mean (SD) age, years 66.5 (13.4) 66.2 (13.5) 67.8 (12.1)
Female, n (%) 186 (73.8) 251 (78.7) 111 (81.0)
Mean (SD) status score 0.14 (1.12) −0.54 (1.25) −0.64 (1.23)
Mean (SD) CDS 4.8 (3.9) 5.1 (3.7) 5.4 (3.7)
Patients starting with
antidepressant
n = 723 n = 1086 n = 392
Mean (SD) age, years 49.4 (17.9) 46.5 (16.1) 49.3 (17.0)
Female 431 (59.6) 681 (62.7) 249 (63.5)
Mean (SD) status score −0.03 (1.15) −0.70 (1.33) −0.89 (1.34)
Mean (SD) CDS 2.3 (2.9) 2.2 (2.9) 2.4 (3.1)
Values are numbers (percentages) unless stated otherwise.
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the slight unequal distribution of medication classes over both
arms. In the appendix additional information is provided: health
characteristics are presented in Table A1, information at cluster
level in Table A2 and on eligible patients without counseling in
Table A3.
In a secondary analysis we compared baseline characteristics
for patients with counseling (PP) to patients in the usual care
arm. Patients with counseling starting with RAS-inhibitors (p =
0.049) or statins (p = 0.04) where slightly older compared
to patients with usual care. Other characteristics were not
significantly different.
The most important reasons for not delivering the
intervention were: no telephone number available (186,
32%), patient could not be reached (185, 31%), was not
interested (83, 14%), or refused cooperation (44, 7%). On
average the call lasted 8.3 min [Standard Deviation (SD)
4.4] and the average preparation time was 6.2 min (4.7).
The pharmacists (PharmD) were responsible for 36% of the
calls, pharmacy practitioners for 43% and technicians for
17%. In 79.5% of the calls all five knowledge items were
reported to be discussed. These items included knowledge
about reason of use (indication), mechanism of action, duration
of treatment, correct moment of intake and possible side
effects.
Doubts about necessity were discussed in 93.1% of the calls,
concerns about side effects in 91.5% and experiences with
side effects in 94.8%. According to the pharmacists 31.0% of
the patients experienced side effects. In patients starting with
antidepressants this proportion was higher compared to other
medication classes (χ2-test p< 0.005).
Primary Outcome Measures
Overall
In the overall ITT analysis we found a mean adherence
rate (MPRm) of 74.7% (SD 37.5) for intervention patients
and 74.5% (SD 37.9) for control patients (see Table 2). The
proportion adherent patients (MPRm≥80%) was 69.0% in
the intervention arm and 69.9% in the usual care arm and
differences between intervention and usual care arms were
not significantly different on both outcomes. Patients with
counseling (PP-analysis) were not significantly more adherent
(78.5% respectively 74.3%, see Table 2). However, when adjusted
for age, gender, medication class and status score, the adjusted
model demonstrated statistically higher adherence (5.79%
TABLE 2 | Effect of telephone counseling on adherence expressed as mean adherence rate, proportion of adherent patients and discontinuation.
Variable Usual care Intervention arm (ITT) Patients with counseling (PP) ITT-analysis PP-analysis
Effect size* (95% CI) Effect size* (95% CI)
Overall n = 3637 n = 3094 n = 1054
Mean adherence (SD) 74.5 (37.9) 74.7 (37.5) 78.5 (35.4) −1.07 (−8.13, 4.15) 3.96 (−2.34, 10.3)
Adherence ≥80%, % (n) 69.9 (2.519) 69.0 (2.134) 74.3 (783) 0.92 (0.68, 1.27) 1.30 (0.93, 2.00)
Discontinued, % (n) 33.2 (1.208) 34.6 (1.069) 33.4 (352) 1.08 (0.82, 1.37) 0.96 (0.70, 1.21)
RAS−inhibitor users n = 1317 n = 850 n = 257
Mean adherence (SD) 78.5 (36.6) 84.1 (31.6) 87.6 (26.4) 5.16 (1.17, 10.03) 8.44 (2.01, 13.4)
Adherence ≥80%, % (n) 74.9 (987) 81.4 (692) 84.1 (216) 1.43 (1.11, 1.99) 1.71 (1.11, 2.62)
Discontinued, % (n) 27.9 (367) 22.6 (192) 21.8 (56) 0.77 (0.69, 0.91) 0.73 (0.56, 1.02)
Statin users n = 1345 n = 839 n = 268
Mean adherence (SD) 75.1 (36.8) 80.5 (32.4) 85.2 (29.0) 4.08 (−0.81, 6.62) 8.97 (3.51, 12.1)
Adherence ≥80%, % (n) 68.9 (926) 75.1 (630) 81.3 (218) 1.27 (0.86, 1.54) 1.83 (1.16, 2.49)
Discontinued, % (n) 32.2 (433) 28.4 (238) 28.0 (75) 0.87 (0.73, 1.10) 0.82 (0.65,1.15)
Bisphosphonate users n = 252) n = 319 n = 137
Mean adherence (SD) 73.3 (38.1) 75.2 (38.4) 84.3 (31.7) −0.54 (−9.43,6.14) 10.2 (1.98, 16.4)
Adherence ≥80%, % (n) 67.1 (169) 70.2 (224) 81.8 (112) 1.00 (0.57, 1.49) 2.15 (1.32, 3.57)
Discontinued, % (n) 39.3 (99) 38.6 (123) 32.9 (45) 1.00 (0.80, 1.40) 0.79 (0.57, 1.25)
Antidepressant users n = 723 n = 1086 n = 392
Mean adherence (SD) 66.8 (40.9) 62.7 (41.7) 65.8 (41.7) −3.78 (−8.15,0.93) −0.55 (−6.04, 6.47)
Adherence ≥80%, % (n) 60.4 (437) 54.1 (588) 60.5 (237) 0.78 (0.59, 1.02) 1.05 (0.78, 1.58)
Discontinued, % (n) 42.7 (309) 47.5 (516) 44.9 (176) 1.17 (1.01, 1.37) 1.04 (0.84, 1.27)
*For “Mean adherence” the effect size is the “risk difference” and for proportion of for “Adherence ≥80%,” it is the Odds Ratio. The likelihood of being adherent is bigger (OR > 1)
or smaller (OR < 1) for participants in the intervention arm compared with participants in the usual care arm. For discontinuation the effect size is the hazard ratio and the hazard
of discontinuing in the first year is bigger (HR>1) or smaller (HR<1) for participants in the intervention arm, compared with participants in the usual care arm. All presented CI’s are
bootstrap CI’s. ITT, intention-to-treat; PP, per protocol; RAS, renin angiotensin system; CI, confidence interval; NNT, number needed to treat.
Bold: ES is outside 95% CI.
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95%CI 2.57, 8.68) and significant more adherent patients in
the intervention arm with an odds ratio of 1.48 (95% CI
1.20, 1.78).
Effect Per Medication Class
The mean adherence rate in patients in the intervention arm
starting with RAS-inhibitors was 84.1% (SD 31.6) compared to
78.5% (SD 36.6) in the usual care arm which is a significant
improvement with a adherence difference based on mixed-effect
models of 5.16% (95% CI 1.17, 10.03) (See Table 2). In the
intervention arm more patients were adherent (MPRm≥80%)
compared to the usual care arm (81.4 vs. 74.9% with OR 1.43,
95% CI 1.11, 1.99). Effects on both outcomes were stronger and
statistically significant for patients with counseling (PP-analysis).
Based on the PP-analysis 16 patients need to be called in order for
one extra patient to be adherent (NNT).
In statin users, patients in the intervention arm had a mean
adherence rate of 80.5% (32.4) compared to 75.1% (36.8) in the
usual care arm, which is a non-significant adherence difference of
4.08% (95% CI−0.81, 6.62). The proportion adherent patients in
the intervention arm (75.1%) was not significantly different from
the proportion in the usual care arm (68.9%) (OR 1.27, 95%CI
0.86, 1.54). Effects on both outcomes for patients with counseling
(PP-analysis) were stronger and statistically significant. The
number needed to call is 14.
In patients starting with bisphosphonates, the mean
adherence rate in intervention arm (75.2%) was not different
from the usual care arm (73.3%) neither was the proportion
of adherent patients (70.2% respectively 67.1%). Effects on
both outcomes for patients with counseling (PP-analysis) were
stronger and statistically significant. The number needed to call
is 11.
For antidepressants we found no significant difference in
adherence rate between patients in the intervention arm (62.7%
SD 41.7) and patients with usual care (66.8%, 40.9). The
proportion adherent patients was also not significantly different
between the arms (54.1% respectively 60.4%with OR 0.78, 95%CI
0.59, 1.02). In the PP-analysis we found no significant difference
between arms.
Intracluster correlation coefficients are presented in Table A4.
Secondary Outcome Measures
In the overall population we found no significant effect of the
intervention on discontinuation in the first year after initiation
(see Table 2). Also in the crude PP-analysis no statistically
significant difference was found but in the adjusted model
discontinuation was lower [hazard ratio (HR) 0.87, 95% CI 0.80,
0.95]. For patients starting with RAS-inhibitors 22.6% of the
patients in the intervention arm discontinued therapy compared
to 27.9% of patients with usual care which is significantly
lower (HR 0.77, 95% CI 0.69, 0.91). The result of the PP-
analysis is comparable but not statistically significant. For
statins and bisphosphonate users, discontinuation rates were not
significantly different (HR 0.87, 95% CI 0.73, 1.10, respectively
0.73, 95% CI 0.56, 1.02).
For patients starting with antidepressants in the intervention
arm 47.5% discontinued compared to 42.7% in the usual care
arm which is a significant different (HR 1.17, 95% CI 1.01,
1.37). However in the PP-analysis 44.9% discontinued in the
intervention arm which is not significantly different from usual
care (HR 1.04, 95%CI 0.84, 1.27)
DISCUSSION
The aim of this study was to assess the effect of telephone
counseling at start of therapy on adherence to RAS-inhibitors,
statins, bisphosphonates, and antidepressants. Overall, no effect
of the intervention was found. Results suggest that adherence
improved for patients starting with RAS-inhibitors, statins or
bisphosphonates. For antidepressants no significant effect was
found.
An interim analysis of this study already showed that
telephone counseling increased satisfaction with information and
increased satisfaction with counseling (Kooy et al., 2015). The
current analysis demonstrates that this increased satisfaction
may translate into improved medication adherence for some
medication classes.
Baseline characteristics of non-registered patients were not
different from patients with counseling. However to prevent
bias, we included all eligible patients based on the prescription
data in the ITT analysis which diluted the potential effect of
the intervention. In line with the expectations, effects in the
PP-analysis were stronger for most outcomes.
The lack of improvement of adherence to antidepressant
therapy is in line with other published studies (Chong et al.,
2013). In a review of interventions focussing on antidepressants
(Chong et al., 2011) authors suggest that educational intervention
alone is not enough and that complex interventions are needed.
However, a recent review indicated that pharmacist care can
improve adherence to antidepressants (Rubio-Valera et al., 2011).
In all studies included in this review, patients had a verified
diagnosis of depression. This is missing in our study and it is
unknown if the medication was prescribed for depression or
other indications like anxiety disorders. Based on the dispensing
data however we know that <20% of patients received a
prescription from a psychiatrist in the 12 months before the
start of the antidepressant. Our study showed that patients
using antidepressants were more likely to experience side
effects. This may have been an additional barrier to improve
adherence. Moreover the counseling might have helped patients
to make a thought-out decision whether or not to continue
treatment, although the effect on adherence might be the same,
(Kooy et al., 2015) Studies for other medication classes like
antidiabetics, (Sacco et al., 2009; Walker et al., 2011), antiplatelet
medication (Rinfret et al., 2013), and statins (Derose et al.,
2013) showed a positive effect of counseling on adherence
or clinical outcomes. In literature we found no trials with
a comparable intervention studied for antihypertensives. In a
trial focussing on bisphosphonates no statistically significant
improvement of adherence was found using a telephone
motivational interviewing intervention (Solomon et al., 2012).
Mean adherence rates and proportion of adherent patients
were relatively high in our study population, both in the
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intervention as in the usual care arm. One explanation might
be that participating pharmacies have already implemented
counseling guidelines to a large extent. Comparison of adherence
between studies should, however, be performed with caution
as the calculated refill-rate is influenced by the method of
calculation and assumptions made (Hess et al., 2006).
Strength of this study is that it was implemented in a real-life
setting and with four different medication classes. The pragmatic
design of the trial and the inclusion of a large number of
pharmacies contributes to the generalizability of the results.
Another strength is that a relatively high proportion of eligible
patients received the intervention. This is high compared to
what is known from literature (Puspitasari et al., 2009; Van de
Steeg-van Gompel et al., 2011; Boeni et al., 2015; Dijk et al.,
2015). Moreover this intervention includes patients irrespective
if they return for a refill or not. So also patients who decided
not to initiate or to discontinue were approached. This is
relevant since a substantial part of the patients discontinue
therapy in the first weeks. Patients not capable of visiting
the pharmacy were also included. Different strategies were
used to enhance treatment fidelity for example by preventing
contamination using a cluster design, providing standardized
training, providing medication class specific interview protocols
and treatment manual, and the obligation for pharmacists
to complete a self-report questionnaire for every selected
patient. Moreover pharmacies received biweekly updates of the
number of patients included with benchmark information. The
intervention was based on theoretical models and guidelines
and the interview protocol contained pre-defined questions and
relevant knowledge items. Moreover the protocol stimulated
pharmacists to ask about patient opinions, for example by asking
“What do you think of getting this medicine?” and to tailor
counseling to patients’ needs which is important to improve
adherence (Andersson et al., 2014). Our study also has its
limitations. Based on the prescription data, more patients should
have received the intervention than were registered. The exact
reason is not known but possible explanations can be that (1) the
computer program did not select all patients, (2) the pharmacist
did not run the program or temporarily stopped including
patients, (3) the pharmacist did call the patient, but failed to
register it, and (4) the pharmacist decided not to call the patient
for unknown reasons. During interviews with some pharmacists
they indicated to have (temporarily) stopped including patients
due to staffing problems.
Patients have different needs and variability between HCP in
the care they provide exists. More research is needed to identify
for which patients and in which setting standard care is sufficient
and for which patients standard care is not sufficient and thus
need additional counseling for example by telephone. Moreover
the cost-effectiveness of the intervention needs to be assessed.
Conclusion
Telephone counseling at start of therapy improved adherence
in patients initiating RAS-inhibitors. The per protocol analysis
indicated an improvement for lipid lowering drugs and
bisphosphonates. No effect for on adherence in patients initiating
antidepressants was found.
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APPENDIX
TABLE A1 | Baseline health characteristics for each group at patient level.
Characteristic Usual care Eligible patients (ITT) Patients with counseling (PP) Overall
USE OF MEDICATION PRECEDING INDEX DATE:
Patients starting with RAS-inhibitor n = 1317 n = 850 n = 257 n = 2167
Antidiabetics (A10) 176 (13.3) 96 (11.2) 36 (14.0) 272 (12.6)
Antithrombotics (B01) 295 (22.3) 227 (26.7) 67 (26.1) 522 (24.1)
Antihypertensives 604 (46.8) 438 (52.5) 134 (53.0) 1042 (49.1)
Patients starting with statin n = 1345 n = 839 n = 268 n = 2184
Antidiabetics (A10) 246 (18.3) 128 (15.3) 34 (12.7) 374 (17.1)
Antithrombotics (B01) 425 (31.6) 279 (33.3) 79 (29.5) 704 (32.2)
Antihypertensives 526 (39.3) 369 (44.5) 126 (47.5) 895 (41.3)
Visit to cardiologist or internist in 12 months before index 465 (34.6) 280 (33.3) 90 (33.6) 745 (34.1)
Patients starting with bisphosphonate n = 252 n = 319 n = 137 n = 571
Calcium suppletion (A12A) 123 (48.8) 163 (51.1) 68 (49.6) 286 (50.1)
Predniso(lo)ne (H02AB06 or H02AB07) 68 (27.0) 85 (26.6) 38 (27.7) 153 (26.8)
Vitamin D (A11CC05) 115 (45.6) 155 (48.6) 67 (48.9) 270 (47.3)
Visit to internist in 12 months before index 248 (98.4) 298 (93.4) 132 (96.4) 546 (95.6)
Patients starting with antidepressant n = 723 n = 1086 n = 392 n = 1809
Antipsychotic (N05) 47 (6.5) 53 (4.9) 12 (3.1) 100 (5.5)
Benzodiazepin (N05BA, N05CD or N05CF) 250 (34.6) 307 (28.3) 109 (27.9) 557 (30.8)
Visit to psychiatrist in 12 months before index 141 (19.5) 276 (25.4) 99 (25.3) 417 (23.1)
Values are number (percentages) unless stated otherwise.
Antihypertensives: Antihypertensives (C02) + Diuretics (C03) + Beta blocking agents (BBA, C07) + Calcium channel blockers (CCB, C08) + RAS inhibitors (C09)).
TABLE A2 | Baseline socio-demographic and health characteristics for each group at cluster level.
Characteristic Usual care Eligible patients (ITT) Patients with counseling (PP) Overall
GENDER (NO/CLUSTER)
Female 38.2 (34.3) 34.3 (41.2) 12.6 (17.6) 72.5 (85.7)
Male 31.7 (44.1) 25.2 (30.6) 8.0 (10.0) 56.9 (64.0)
PHARMACY INCLUSION PHASE
Phase 1 113.9 (102.5) 95.2 (76.3) 33.4 (29.8) 209.2 (158.3)
Phase 2 14.5 (14.4) 14.4 (13.7) 3.8 (2.8) 28.9 (24.4)
AGE GROUPS (NO/CLUSTER)
18–50 19.7 (22.5) 20.3 (28.2) 6.4 (11.5) 40.0 (49.3)
51–65 25.8 (37.4) 19.8 (25.4) 6.6 (8.6) 45.6 (52.1)
>65 24.5 (35.5) 19.4 (26.9) 7.6 (11.5) 43.8 (51.4)
NUMBER OF PATIENTS STARTING
Overall 69.9 (91.2) 59.5 (70.1) 20.7 (26.8) 129.4 (149.0)
RAS-inhibitors 25.3 (48.1) 16.3 (31.0) 9.5 (10.7) 41.7 (49.3)
Statins 25.9 (48.7) 16.1 (33.5) 9.9 (14.0) 42.0 (51.4)
Bisphosphonates 4.8 (8.1) 6.1 (11.4) 5.7 (8.2) 11.0 (11.6)
Antidepressants 13.9 (23.3) 20.9 (40.5) 16.3 (23.4) 34.8 (39.9)
CHRONIC DISEASE SCORE
0–1 27.3 (33.0) 24.8 (29.1) 7.9 (11.5) 52.0 (59.9)
2–4 27.3 (33.0) 16.9 (22.7) 5.8 (8.3) 38.4 (43.8)
5–19 21.2 (29.5) 16.5 (21.2) 6.4 (8.0) 37.7 (45.0)
Status score
< –1.0 24.4 (55.4) 20.5 (45.1) 7.7 (18.2) 44.9 (96.1)
–1 to 0.5 24.4 (44.3) 18.0 (29.5) 6.2 (12.2) 42.4 (67.6)
>0.5 21.1 (33.6) 21.1 (35.0) 6.7 (10.7) 42.2 (64.2)
Values are means per cluster (standard deviation) unless stated otherwise.
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TABLE A3 | Baseline socio-demographic and health characteristics for each group at individual level.
Characteristic Usual care Eligible patients (ITT) Patients with counseling (PP) Eligible patients without
counseling
Overall
Overall n = 3637 n = 3094 n = 1054 n = 2040 n = 6731
Mean (SD) age, years 59.0 (15.1) 56.9 (15.9) 58.6 (15.8) 58.0 (15.5) 56.1(15.9)
Female, n (%) 1987 (54.6) 1785 (57.7) 644 (61.1) 3772 (56.0) 1141 (55.9)
Mean (SD) status score −0.44 (1.29) −0.31 (1.20) −0.43 (1.27) −0.38 (1.25) −0.24(1.16)
Mean (SD) CDS 3.3 (3.1) 3.1 (3.1) 3.4 (3.2) 3.2 (3.1) 3.0(3.1)
Starting with RAS-inhibitor n = 1317 n = 850 n = 257 n = 593 n = 2167
Mean (SD) age, years 61.1 (13.7) 62.2 (13.0) 63.8 (12.2) 61.6 (13.4) 61.5 (13.3)
Female, n (%) 710 (53.9) 439 (51.6) 145 (56.4) 1149 (53.0) 294 (49.6)
Mean (SD) status score −0.62 (1.32) −0.01 (1.06) −0.08 (1.18) −0.38 (1.26) 0.02 (1.0)
Mean (SD) CDS 3.3 (3.1) 3.3 (3.0) 3.5 (2.9) 3.3 (3.1) 3.2 (3.0)
Starting with statin n = 1345 n = 839 n = 268 n = 571 n = 2184
Mean (SD) age, years 60.6 (12.6) 61.6 (11.5) 62.5 (11.3) 61.0 (12.2) 61.2 (11.5)
Female, n (%) 660 (49.1) 414 (49.3) 139 (51.9) 1074 (49.2) 275 (48.2)
Mean (SD) status score −0.60 (1.29) −0.02 (0.97) −0.01 (0.98) −0.38 (1.21) −0.03 (0.97)
Mean (SD) CDS 3.4 (2.9) 3.4 (2.8) 3.6 (2.8) 3.4 (2.9) 3.3 (2.8)
Starting with bisphosphonate n = 252 n = 319 n = 137 n = 182 n = 571
Mean (SD) age, years 66.5 (13.4) 66.2 (13.5) 67.8 (12.1) 66.3 (13.5) 64.9 (14.4)
Female, n (%) 186 (73.8) 251 (78.7) 111 (81.0) 437 (76.5) 140 (76.9)
Mean (SD) status score 0.14 (1.12) −0.54 (1.25) −0.64 (1.23) −0.24 (1.24) −0.46 (1.26)
Mean (SD) CDS 4.8 (3.9) 5.1 (3.7) 5.4 (3.7) 5.0 (3.8) 4.9 (3.7)
Starting with antidepressant n = 723 n = 1086 n = 392 n = 694 n = 1086
Mean (SD) age, years 49.4 (17.9) 46.5 (16.1) 49.3 (17.0) 47.7 (16.9) 44.9 (15.4)
Female, n (%) 431 (59.6) 681 (62.7) 249 (63.5) 1112 (61.5) 432 (62.2)
Mean (SD) status score −0.03 (1.15) −0.70 (1.33) −0.89 (1.34) −0.43 (1.30) −0.59 (1.31)
Mean (SD) CDS 2.3 (2.9) 2.2 (2.9) 2.4 (3.1) 2.3 (2.9) 2.0 (2.8)
Values are numbers (percentages) unless stated otherwise.
TABLE A4 | Coefficients of intracluster correlation (ICC).
Medicationclass Refillrate (MPRm) Refillrate (PDC)
Overall 0.022 0.020
RAS-inhibitors 0.032 0.022
Statins 0.011 0.004
Bisphosphonates 0.058 0.036
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